• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Pharmaceutical Market
Pharmaceutical News
Pharmaceutical Stocks
  • Pharmaceutical Market
  • Pharmaceutical News
  • Pharmaceutical Stocks
pharmaceutical investing

Easton Pharmaceuticals Seeks to Get Herbs of Kedem

Bryan Mc Govern
May. 02, 2017 09:17AM PST
Pharmaceutical Investing

Easton Pharmaceuticals signed a letter of intent for the acquisition of Israeli therapeutics company Herbs of Kedem.

Easton Pharmaceuticals (OTC:EAPH) signed a letter of intent for the acquisition of Israeli therapeutics company Herbs of Kedem.
As quoted in the press release:

Herbs of Kedem is an Israeli based company with sales in excess of $2,200,000 US and healthy profit margins with a current net profit of approximately $1,500,000 US with minimal marketing exposure. Herbs of Kedem currently has a total of 10 adult skin care and anti-aging products, 5 hair care and hair loss products, 4 foot and nail care products, 16 skin care products, 6 respiratory tract treatment products and 4 food supplement products. Herbs of Kedem therapeutic natural products with its main ingredients being sourced from the Dead Sea and with distribution channels through many European and recently forged North American distributors, Easton believes the revenue capabilities of these products can grow exponentially as the quality is unmatched. Most of the products including its hair restoration product to treat male pattern baldness have undergone clinical trials. Easton expects to soon announce testing and sales trials of certain products in select stores at a Canadian Retail Pharmacy Chain, Shoppers Drug Mart, with over 1,253 locations in Canada. Additional updates on the proposed acquisition of Herbs Of Kadem will be announced as they become available.

Click here to read the full press release.

Source: www.marketwired.com

pharmaceutical investing clinical trials canada easton pharmaceuticals shoppers drug mart
The Conversation (0)

Go Deeper

AI Powered
Senior woman doing exercises alongside closeup of DNA.

5 US Longevity and Anti-aging Stocks to Watch

A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

Latest News

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

U.S. Patent allowance received for PTSD discovery programme

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Pharmaceutical Investing Stocks

InMed Pharmaceuticals

InMed Pharmaceuticals (INM)
INM

Cardiol Therapeutics

Cardiol Therapeutics (CRDL:CC)
CRDL:CC

Principal Technologies

Principal Technologies (PTEC:CC)
PTEC:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES